Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Zilucoplan Improved Efficacy Outcomes in Myasthenia Gravis

Publish date:: February 19, 2020

Key clinical point: Zilucoplan, a self-administered complement C5 inhibitor, improved measures of muscle weakness and daily function in patients with generalized myasthenia gravis.

Major finding: The mean change in Quantitative Myasthenia Gravis score was –6.0 points for zilucoplan 0.3 mg/kg and –3.2 for placebo (P = .05).

Study details: A randomized, placebo-controlled, phase 2 study including 44 adult patients with acetylcholine receptor autoantibody–positive generalized myasthenia gravis.

Disclosures: Ra Pharmaceuticals funded the study. The lead author reported disclosures related to Ra Pharmaceuticals, Alexion Pharmaceuticals, argenx, Viela Bio, and others.

Citation:

Howard Jr JF et al. JAMA Neurol. 2020 Feb 17. doi: 10.1001/jamaneurol.2019.5125.

This Week's Must Reads

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Study links sleep meds and dementia risk in older adults,

Childhood Hodgkin survivors have neurocognitive impairment,

Obesity, hypoxia predict severity in children with COVID-19,

Long-term safety and efficacy of teriflunomide for relapsing MS,

Must Reads in Rare Diseases

Childhood Hodgkin survivors have neurocognitive impairment,

Gene-replacement therapy shows promise in X-linked myotubular myopathy,

Ataluren delays disease milestones in patients with nonsense mutation DMD,

Nusinersen provides continued benefits to presymptomatic children with SMA,

CBD for LGS: Fewer seizures, but thrombocytopenia risk,